RT Journal Article
SR Electronic
T1 Impact of pathogen reduction technologies on immunological properties of the COVID-19 convalescent plasma
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.02.20205567
DO 10.1101/2020.10.02.20205567
A1 Kostin, A.
A1 Lundgren, M.
A1 Bulanov, A.
A1 Ladygina, E.
A1 Chirkova, K.
A1 Gintsburg, A.
A1 Logunov, D.
A1 Dolzhikova, I.
A1 Shcheblyakov, D.
A1 Borovkova, N.
A1 Godkov, M.
A1 Bazhenov, A.
A1 Shustov, V.
A1 Bogdanova, A.
A1 Kamalova, A.
A1 Ganchin, V.
A1 Dombrovskiy, E.
A1 Volkov, S.
A1 Drozdova, N.
A1 Petrikov, S.
YR 2020
UL http://medrxiv.org/content/early/2020/10/05/2020.10.02.20205567.abstract
AB Background and Objectives In the absence of a vaccine or specific antiviral drugs against SARS-CoV-2 COVID-19 convalescent plasma became one of the experimental treatment options in many countries. Aim of this study was to assess the impact of different pathogen reduction technologies on the immunological properties of COVID-19 convalescent plasma.Materials and Methods In our experiment 140 doses of plasma collected by plasmapheresis from COVID-19 convalescent donors were subjected to pathogen reduction with one of three different methods: methylene blue (M), riboflavin (R), and amotosalen (A). To conduct a paired two-sample comparison each plasma dose was divided into 2 that were treated by one of these technologies. The titres of SARS-CoV2 neutralizing antibodies (NtAbs) and levels of specific immunoglobulins to RBD, S- and N-proteins of SARS-CoV-2 were measured before and after pathogen reduction.Results All methods reduced NtAbs titers significantly but not at the same grade: among units with the initial titre 80 or above, 81% of units had unchanged titres while 19% decreased by 1 step after methylene blue; 60% unchanged and 40% - decreased by 1 step after amotosalen; 43% unchanged, 67% a one-step decrease and 6% - a two-step decrease after riboflavin. Pairwise two-sample comparisons (M vs A, M vs R and A vs R) revealed the most prominent and statistically significant decrease in all studied parameters (except anti-RBD) following pathogen reduction with riboflavin.Conclusion Pathogen reduction with amotosalen and methylene blue provides the greater likelihood of preserving the immunological properties of the COVID-19 convalescent plasma compared to riboflavin.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was made possible in the context of Moscow Government COVID-19 Convalescent Plasma Program. Stanislav Volkovs research is partially supported by the Swedish Research Council and the Crafoord foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Moscow Government Health Care DepartmentAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data referred to at this manuscript is available